共0篇 平均IF=NaN (-)更多分析

    加载中

    logo
    The human melanoma proteome atlas-Defining the molecular pathology. Betancourt Lazaro Hiram,Gil Jeovanis,Kim Yonghyo,Doma Viktória,Çakır Uğur,Sanchez Aniel,Murillo Jimmy Rodriguez,Kuras Magdalena,Parada Indira Pla,Sugihara Yutaka,Appelqvist Roger,Wieslander Elisabet,Welinder Charlotte,Velasquez Erika,de Almeida Natália Pinto,Woldmar Nicole,Marko-Varga Matilda,Pawłowski Krzysztof,Eriksson Jonatan,Szeitz Beáta,Baldetorp Bo,Ingvar Christian,Olsson Håkan,Lundgren Lotta,Lindberg Henrik,Oskolas Henriett,Lee Boram,Berge Ethan,Sjögren Marie,Eriksson Carina,Kim Dasol,Kwon Ho Jeong,Knudsen Beatrice,Rezeli Melinda,Hong Runyu,Horvatovich Peter,Miliotis Tasso,Nishimura Toshihide,Kato Harubumi,Steinfelder Erik,Oppermann Madalina,Miller Ken,Florindi Francesco,Zhou Qimin,Domont Gilberto B,Pizzatti Luciana,Nogueira Fábio C S,Horvath Peter,Szadai Leticia,Tímár József,Kárpáti Sarolta,Szász A Marcell,Malm Johan,Fenyö David,Ekedahl Henrik,Németh István Balázs,Marko-Varga György Clinical and translational medicine The MM500 study is an initiative to map the protein levels in malignant melanoma tumor samples, focused on in-depth histopathology coupled to proteome characterization. The protein levels and localization were determined for a broad spectrum of diverse, surgically isolated melanoma tumors originating from multiple body locations. More than 15,500 proteoforms were identified by mass spectrometry, from which chromosomal and subcellular localization was annotated within both primary and metastatic melanoma. The data generated by global proteomic experiments covered 72% of the proteins identified in the recently reported high stringency blueprint of the human proteome. This study contributes to the NIH Cancer Moonshot initiative combining detailed histopathological presentation with the molecular characterization for 505 melanoma tumor samples, localized in 26 organs from 232 patients. 10.1002/ctm2.473
    Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. International journal of molecular sciences Similar to other malignancies, TCGA network efforts identified the detailed genomic picture of skin melanoma, laying down the basis of molecular classification. On the other hand, genome-wide association studies discovered the genetic background of the hereditary melanomas and the susceptibility genes. These genetic studies helped to fine-tune the differential diagnostics of malignant melanocytic lesions, using either FISH tests or the myPath gene expression signature. Although the original genomic studies on skin melanoma were mostly based on primary tumors, data started to accumulate on the genetic diversity of the progressing disease. The prognostication of skin melanoma is still based on staging but can be completed with gene expression analysis (DecisionDx). Meanwhile, this genetic knowledge base of skin melanoma did not turn to the expected wide array of target therapies, except the BRAF inhibitors. The major breakthrough of melanoma therapy was the introduction of immune checkpoint inhibitors, which showed outstanding efficacy in skin melanoma, probably due to their high immunogenicity. Unfortunately, beyond , mutations and tumor mutation burden, no clinically validated predictive markers exist in melanoma, although several promising biomarkers have been described, such as the expression of immune-related genes or mutations in the IFN-signaling pathway. After the initial success of either target or immunotherapies, sooner or later, relapses occur in the majority of patients, due to various induced genetic alterations, the diagnosis of which could be developed to novel predictive genetic markers. 10.3390/ijms23105384